Publication:
Case Report: Effectiveness Of Brexpiprazole And Esketamine/ketamine Combination: A Novel Therapeutic Strategy In Five Cases Of Treatment-resistant Depression

Simple item page
dc.contributor.authorLai Fong Chanen_US
dc.contributor.authorLuke Sy-Cherng Woonen_US
dc.contributor.authorNuur Asyikin Mohd Shukoren_US
dc.contributor.authorChoon Leng Euen_US
dc.contributor.authorNurazah Ismailen_US
dc.contributor.authorSong Jie Chinen_US
dc.contributor.authorNik Ruzyanei Nik Jaafaren_US
dc.contributor.authorAzlin Baharudinen_US
dc.date.accessioned2024-05-28T05:58:44Z
dc.date.available2024-05-28T05:58:44Z
dc.date.issued2022
dc.date.submitted2022-7-27
dc.descriptionFront. Psychiatry, 22 July 2022 Sec. Psychopharmacologyen_US
dc.description.abstractA significant proportion of patients with treatment-resistant depression do not attain functional recovery despite administration of multiple steps of pharmacotherapeutic strategies. This highlights the elusiveness of meeting unmet needs in existing pharmacotherapies for treatment-resistant depression. There is accumulating evidence that antidepressant agents involving the glutamatergic system such as brexpiprazole and esketamine/ketamine have more rapid onset of action and potentially improved effectiveness as an augmentation therapy in treatment-resistant depression. This case series aimed to report five complex cases of unipolar and bipolar treatment-resistant depression where conventional treatment strategies were inadequate in managing high risk suicidal behavior and achieving functional recovery. We discussed further the possible synergistic mechanisms of the novel combination strategy of brexpiprazole and esketamine/ketamine, clinical and patient factors that influenced treatment response, challenges with this combination strategy and implications for future practice and research.en_US
dc.identifier.citationChan LF, Woon LS-C, Mohd Shukor NA, Eu CL, Ismail N, Chin SJ, Nik Jaafar NR and Baharudin A (2022) Case report: Effectiveness of brexpiprazole and esketamine/ketamine combination: A novel therapeutic strategy in five cases of treatment-resistant depression. Front. Psychiatry 13:890099. doi: 10.3389/fpsyt.2022.890099en_US
dc.identifier.doi10.3389/fpsyt.2022.890099
dc.identifier.epage10
dc.identifier.issn1664-0640
dc.identifier.issue890099
dc.identifier.other1961-3
dc.identifier.spage1
dc.identifier.urihttps://www.frontiersin.org/articles/10.3389/fpsyt.2022.890099/full
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/6897
dc.identifier.volume13
dc.language.isoenen_US
dc.publisherFrontiers Media S.Aen_US
dc.relation.ispartofFrontiers in Psychiatryen_US
dc.subjecttreatment-resistant depression, effectiveness, ketamine, brexpiprazole, esketamineen_US
dc.titleCase Report: Effectiveness Of Brexpiprazole And Esketamine/ketamine Combination: A Novel Therapeutic Strategy In Five Cases Of Treatment-resistant Depressionen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Case report Effectiveness of brexpiprazole and esketamineketamine combination A novel therapeutic strategy in five cases of treatment-resistant depression.pdf
Size:
1.18 MB
Format:
Adobe Portable Document Format
Download

Collections

Other Publications